Powered by NAi’s biology-first Bayesian causal AI, BPGbio has generated a deep and diversified discovery pipeline across wide-range disease areas. This pipeline demonstrates NAi’s capability to uncover novel, high-confidence targets and programs far beyond any single pathway or therapeutic area.

Novel Targets Discovered by NAi

High-confidence and Diversified Areas of Target Biology for Drug Discovery

The 75 targets discovered by the NAi platform span multiple biological mechanisms and disease pathways. Whether it’s mitochondrial metabolism, protein homeostasis, cytoskeletal regulation, signal transduction, or immune modulation, NAi’s causal modeling finds high-value biology across distinct therapeutic domains.

75	6	5	8
Target Validation Programs	Drug Discovery Programs	IND Approved	Clinical Development

Contact BD@BPGbio.com to discuss licensing and partnership opportunities.

BPGbio Robust Clinical Pipeline

Indication	Molecule / Asset	Known Activity	Discovery	Hit to Lead	Lead	IND	Phase 1	Phase 2
Clinical Programs

Glioblastoma (GBM)	BPM31510-IV	Radiation Sensitizer
Pancreatic Cancer	BPM31510-IV	Chemotherapy Sensitizer
Primary CoQ10 Deficiency	BPM31510-IV	Direct Replacement
Squamous Cell Carcinoma	BPM31510-T	Wound Healing
Epidermolysis Bullosa	BPM31510-T	Wound Healing
Sarcopenia	BPM31510-Oral	Mitochondrial Respiration
Solid and Liquid Tumors	BRG399	Tubulin Polymerization
Secondary CVD Prevention	BRG399	Neutrophil Inflammation
BPM31510, has received FDA Rare Pediatric Disease Designation for Primary Coenzyme Q10 Deficiency (PCQD) and Epidermolysis Bullosa (EB) respectively. The company is planning a potential pivotal trial in Primary CoQ10 Deficiency. Upon Approval, both designations provide BPGbio eligibility for a Priority Review Voucher (PRV).
Indication	Molecule / Asset	Target Class	Discovery	Hit to Lead	Lead	IND	Phase 1	Phase 2
Drug Discovery Programs
Huntington Disease	BPG812	Ubiquitin Proteosomal
Oncology	BPG1438	Targeted Protein Degradation
Parkinson’s Disease	BRGP0811	Oxidoreductase Target
Oncology	Hit Molecules	DNA RNA Helicases
Oncology	Hit Molecules	Ubiquitin Proteosomal
Angiogenesis	BRG0001

Novel Target Biology Discovery by the NAi Platform

Indication	Pathway / Biology Area	# of Targets
Parkinson’s Disease (19 targets)	Cytoskeleton, adhesion, migration	8
		ECM & stromal biology	2
		Stress & metabolic signaling	4
		DNA damage & gene regulation	2
		RNA processing & gene regulation	3

Alzheimer’s Disease (8 targets)	ER protein folding & UPR	3
		Mitochondrial ATP synthesis (OXPHOS)	2
		Cytoskeleton & membrane trafficking	3

Huntington’s Disease	Autophagy-Proteostasis Cross-Talk	1

Autism (11 targets)	Antigen processing & immunity	4
		Apoptosis	1
		ER proteostasis / UPR	2
		RNA metabolism & translation control	2
		GPCR signaling	1
		Mitochondrial ion/metabolic regulation	1

Oncology (28 Targets)	Protein folding, ER stress & proteostasis	8
		RNA processing & translational control	7
		Mitochondrial biology & metabolism	3
		Cytoskeleton & intracellular transport	4
		Signal transduction (phosphatases)	2
		ECM / developmental regulation & chomatin architecture	4

Diabetes (4 targets)	Energy metabolism: glycolysis & TCA	3
Diabetes (4 targets)		Protein folding / molecular chaperones	1

Obesity (4 targets)	Extracellular Matrix / Structural Proteins	2
		Metabolism / Lipid Biosynthesis	1
		Ubiquitin-Proteasome System / Protein Degradation	1

BPGbio First-In-Class Diagnostic Pipeline